Business Model Breakdown
How Absci Corp Makes Money
ABSI
Market Cap
$468M
Annual Revenue
$3M
Profit Margin
0.0%
Employees
156
The Short Version
Absci Corp develops and utilizes an innovative 'Integrated Drug Creation™' platform, which combines generative artificial intelligence with high-throughput wet-lab experiments, to accelerate the discovery and development of novel protein-based drug candidates. They partner with pharmaceutical companies to leverage their AI platform to design and optimize new therapeutic proteins, aiming to reduce the time and cost typically associated with traditional drug discovery. Their value proposition is to make drug creation faster, smarter, and more effective for their partners.
Where the Revenue Comes From
Collaboration agreements and research fees from pharmaceutical partners (~100% of current revenue)
Milestone payments tied to progression of drug candidates developed through their platform (potential future major contributor)
Potential royalties on commercialized drugs discovered using their technology (long-term potential)
Who buys: Large pharmaceutical companies, biotech firms, and academic research institutions seeking to outsource or enhance their drug discovery processes using advanced AI.
Why It Works (Competitive Advantages)
- ✔Proprietary AI-powered 'Integrated Drug Creation' platform
- ✔Unique combination of generative AI and high-throughput wet-lab experiments
- ✔Proprietary biological data generation for AI training
Economic Moat: Narrow (Intangible Assets/IP (proprietary AI algorithms, unique data sets, patents on platform), Switching Costs (partnerships require significant integration, making switching difficult))
What Our Analysis Says
DVR Score as of April 11, 2026
Absci's score has been significantly downgraded due to material deterioration in its financial performance and a major clinical setback. The Q4 2025 earnings miss was substantial, with full-year 2025 revenue declining 38% YoY, signaling a clear operational stumble. Furthermore, the explicit halting of the ABS-101 program due to disappointing Phase 1 data is a critical blow to its internal pipeline. While the AI-powered drug discovery platform still offers long-term potential in a massive TAM, the accelerating cash burn ($94M TTM FCF burn) and a short cash runway (18 months) amplify financial risk and necessitate likely dilutive financing. The extremely high P/S ratio (167x) for a declining-revenue company is unsustainable. The strong insider buy by the CIO offers a glimmer of confidence but is outweighed by these significant red flags. The path to 10x growth is now considerably more speculative and fraught with immediate financial challenges.